Researchers tracked over 10,000 patients and found the risk of self-harm was highest before starting gabapentinoids and again shortly after stopping, highlighting key periods for clinical monitoring.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
A study found no statistically significant differences in treatment failure rates between substitution monotherapy and add-on therapy for women with idiopathic generalized epilepsy, indicating both options are viable.
“Approval of an immediate-use intranasal diazepam treatment that can be given at any time—even while a child is actively seizing—in this young age group is an important advance for the epilepsy community.”